Topical bacteriocin therapy with epidermicin NI01 for dermatological infections (TOBRADERM)

使用表皮霉素 NI01 局部细菌素治疗皮肤感染 (TOBRADERM)

基本信息

  • 批准号:
    10071961
  • 负责人:
  • 金额:
    $ 89.04万
  • 依托单位:
  • 依托单位国家:
    英国
  • 项目类别:
    Collaborative R&D
  • 财政年份:
    2024
  • 资助国家:
    英国
  • 起止时间:
    2024 至 无数据
  • 项目状态:
    未结题

项目摘要

Amprologix is a company developing novel antibiotics to meet the global threat of antimicrobial resistance (AMR). AMR happens when bacteria become resistant to antibiotics and results in treatment failure and increased death from 'drug resistant' infections. These infections killed over 1.2 million people in 2019 and new antibiotics are urgently needed. If we don't develop new antibiotics, our current medical system may fail and things like cancer therapy and routine surgery may result in a fatal infection.In this TOBRADERM project, Amprologix will test a new antibiotic compound, epidermicin NI01, for treating skin infections, which affect millions of people every year in the UK and are the cause of more than 10% of all antibiotic prescriptions. Skin infections can be minor but can also result in severe and fatal outcomes, and they are increasingly complicated by AMR. We will develop epidermicin to be used externally (topical application), being applied directly to infected areas. This increases the killing action but also helps preserve current antibiotics, taken orally or by injection, for use against serious infections, like those in the blood.Epidermicin NI01 is from a new class of antibiotic compound, the bacteriocins (small protein-like molecules). Whilst bacteriocins are not used to treat patients yet, epidermicin has many features that increase the chance of it being a successful drug. These features include properties that minimise any risks that have stopped development of previous bacteriocins: it has very potent activity against globally leading pathogens ('superbugs'), including those that are resistant to current antibiotics and the leading causes of skin infections; toxicity is extremely low, even in recent safety tests in animals; resistance is very unlikely to occur due to the novel way it kills target bacteria; and we have developed an extremely low-cost production system. Epidermicin will also not kill all kinds of bacteria meaning it will target the main pathogens, leaving other skin bacteria unharmed, protecting the 'microbiome'.Epidermicin is an extremely promising new antibiotic and success in the TOBRADERM project will allow Amprologix to access new drug markets, helping it grow into a global leader in 'topical therapeutics'. This will create jobs, generate income for the company and enable development of a new drug to treat skin infections, potentially benefitting over 1 million people a year in the UK.
Amprologix 是一家开发新型抗生素的公司,旨在应对全球抗菌素耐药性 (AMR) 的威胁。当细菌对抗生素产生耐药性并导致治疗失败并增加“耐药”感染导致的死亡时,就会发生抗菌素耐药性。 2019 年,这些感染导致超过 120 万人死亡,迫切需要新的抗生素。如果我们不开发新的抗生素,我们当前的医疗系统可能会失败,癌症治疗和常规手术等可能会导致致命的感染。在这个 TOBRADERM 项目中,Amprologix 将测试一种新的抗生素化合物表皮霉素 NI01,用于治疗皮肤感染,皮肤感染每年影响英国数百万人,占所有抗生素处方的 10% 以上。皮肤感染可能很轻微,但也可能导致严重和致命的后果,而且抗菌素耐药性使情况变得越来越复杂。我们将开发外用表皮霉素(局部应用),直接应用于感染部位。这增强了杀灭作用,但也有助于保留现有的口服或注射抗生素,用于对抗严重感染,如血液中的感染。Epidermicin NI01 来自一类新型抗生素化合物,即细菌素(类似蛋白质的小分子)。虽然细菌素尚未用于治疗患者,但表皮霉素具有许多特性,增加了其成为成功药物的机会。这些特性包括最大限度地减少先前细菌素开发停止的任何风险的特性:它对全球领先的病原体(“超级细菌”)具有非常有效的活性,包括那些对当前抗生素具有抗药性的病原体和皮肤感染的主要原因;即使在最近的动物安全测试中,毒性也极低;由于它杀死目标细菌的方式新颖,因此不太可能出现耐药性;我们开发了一种成本极低的生产系统。 Epidermicin 也不会杀死所有种类的细菌,这意味着它会针对主要病原体,而不会伤害其他皮肤细菌,从而保护“微生物群”。Epidermicin 是一种极具前景的新型抗生素,TOBRADERM 项目的成功将使 Amprologix 进入新药市场,帮助其成长为“局部治疗”的全球领导者。这将为公司创造就业机会、创造收入,并促进治疗皮肤感染的新药的开发,每年可能使超过 100 万人受益。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

其他文献

Internet-administered, low-intensity cognitive behavioral therapy for parents of children treated for cancer: A feasibility trial (ENGAGE).
针对癌症儿童父母的互联网管理、低强度认知行为疗法:可行性试验 (ENGAGE)。
  • DOI:
    10.1002/cam4.5377
  • 发表时间:
    2023-03
  • 期刊:
  • 影响因子:
    4
  • 作者:
  • 通讯作者:
Differences in child and adolescent exposure to unhealthy food and beverage advertising on television in a self-regulatory environment.
在自我监管的环境中,儿童和青少年在电视上接触不健康食品和饮料广告的情况存在差异。
  • DOI:
    10.1186/s12889-023-15027-w
  • 发表时间:
    2023-03-23
  • 期刊:
  • 影响因子:
    4.5
  • 作者:
  • 通讯作者:
The association between rheumatoid arthritis and reduced estimated cardiorespiratory fitness is mediated by physical symptoms and negative emotions: a cross-sectional study.
类风湿性关节炎与估计心肺健康降低之间的关联是由身体症状和负面情绪介导的:一项横断面研究。
  • DOI:
    10.1007/s10067-023-06584-x
  • 发表时间:
    2023-07
  • 期刊:
  • 影响因子:
    3.4
  • 作者:
  • 通讯作者:
ElasticBLAST: accelerating sequence search via cloud computing.
ElasticBLAST:通过云计算加速序列搜索。
  • DOI:
    10.1186/s12859-023-05245-9
  • 发表时间:
    2023-03-26
  • 期刊:
  • 影响因子:
    3
  • 作者:
  • 通讯作者:
Amplified EQCM-D detection of extracellular vesicles using 2D gold nanostructured arrays fabricated by block copolymer self-assembly.
使用通过嵌段共聚物自组装制造的 2D 金纳米结构阵列放大 EQCM-D 检测细胞外囊泡。
  • DOI:
    10.1039/d2nh00424k
  • 发表时间:
    2023-03-27
  • 期刊:
  • 影响因子:
    9.7
  • 作者:
  • 通讯作者:

的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('', 18)}}的其他基金

An implantable biosensor microsystem for real-time measurement of circulating biomarkers
用于实时测量循环生物标志物的植入式生物传感器微系统
  • 批准号:
    2901954
  • 财政年份:
    2028
  • 资助金额:
    $ 89.04万
  • 项目类别:
    Studentship
Exploiting the polysaccharide breakdown capacity of the human gut microbiome to develop environmentally sustainable dishwashing solutions
利用人类肠道微生物群的多糖分解能力来开发环境可持续的洗碗解决方案
  • 批准号:
    2896097
  • 财政年份:
    2027
  • 资助金额:
    $ 89.04万
  • 项目类别:
    Studentship
A Robot that Swims Through Granular Materials
可以在颗粒材料中游动的机器人
  • 批准号:
    2780268
  • 财政年份:
    2027
  • 资助金额:
    $ 89.04万
  • 项目类别:
    Studentship
Likelihood and impact of severe space weather events on the resilience of nuclear power and safeguards monitoring.
严重空间天气事件对核电和保障监督的恢复力的可能性和影响。
  • 批准号:
    2908918
  • 财政年份:
    2027
  • 资助金额:
    $ 89.04万
  • 项目类别:
    Studentship
Proton, alpha and gamma irradiation assisted stress corrosion cracking: understanding the fuel-stainless steel interface
质子、α 和 γ 辐照辅助应力腐蚀开裂:了解燃料-不锈钢界面
  • 批准号:
    2908693
  • 财政年份:
    2027
  • 资助金额:
    $ 89.04万
  • 项目类别:
    Studentship
Field Assisted Sintering of Nuclear Fuel Simulants
核燃料模拟物的现场辅助烧结
  • 批准号:
    2908917
  • 财政年份:
    2027
  • 资助金额:
    $ 89.04万
  • 项目类别:
    Studentship
Assessment of new fatigue capable titanium alloys for aerospace applications
评估用于航空航天应用的新型抗疲劳钛合金
  • 批准号:
    2879438
  • 财政年份:
    2027
  • 资助金额:
    $ 89.04万
  • 项目类别:
    Studentship
Developing a 3D printed skin model using a Dextran - Collagen hydrogel to analyse the cellular and epigenetic effects of interleukin-17 inhibitors in
使用右旋糖酐-胶原蛋白水凝胶开发 3D 打印皮肤模型,以分析白细胞介素 17 抑制剂的细胞和表观遗传效应
  • 批准号:
    2890513
  • 财政年份:
    2027
  • 资助金额:
    $ 89.04万
  • 项目类别:
    Studentship
CDT year 1 so TBC in Oct 2024
CDT 第 1 年,预计 2024 年 10 月
  • 批准号:
    2879865
  • 财政年份:
    2027
  • 资助金额:
    $ 89.04万
  • 项目类别:
    Studentship
Understanding the interplay between the gut microbiome, behavior and urbanisation in wild birds
了解野生鸟类肠道微生物组、行为和城市化之间的相互作用
  • 批准号:
    2876993
  • 财政年份:
    2027
  • 资助金额:
    $ 89.04万
  • 项目类别:
    Studentship

相似海外基金

Oral microbiome and inflammatory status in antimicrobially-treated oral cancer patients
接受抗菌药物治疗的口腔癌患者的口腔微生物组和炎症状态
  • 批准号:
    10642765
  • 财政年份:
    2022
  • 资助金额:
    $ 89.04万
  • 项目类别:
Oral microbiome and inflammatory status in antimicrobially-treated oral cancer patients
接受抗菌药物治疗的口腔癌患者的口腔微生物组和炎症状态
  • 批准号:
    10685029
  • 财政年份:
    2022
  • 资助金额:
    $ 89.04万
  • 项目类别:
Project 3: Functional Microbiome and Host Signatures in Transition from Commensal to pathogen
项目 3:从共生到病原体转变的功能微生物组和宿主特征
  • 批准号:
    10614695
  • 财政年份:
    2020
  • 资助金额:
    $ 89.04万
  • 项目类别:
Probiotics that moderate pH and antagonize pathogens to promote oral health
益生菌可调节 pH 值并对抗病原体,促进口腔健康
  • 批准号:
    10175495
  • 财政年份:
    2020
  • 资助金额:
    $ 89.04万
  • 项目类别:
Project 3: Functional Microbiome and Host Signatures in Transition from Commensal to pathogen
项目 3:从共生到病原体转变的功能微生物组和宿主特征
  • 批准号:
    10226289
  • 财政年份:
    2020
  • 资助金额:
    $ 89.04万
  • 项目类别:
Project 3: Functional Microbiome and Host Signatures in Transition from Commensal to pathogen
项目 3:从共生到病原体转变的功能微生物组和宿主特征
  • 批准号:
    10024961
  • 财政年份:
    2020
  • 资助金额:
    $ 89.04万
  • 项目类别:
Temporal dynamics of MDRO eradication after FMT
FMT 后 MDRO 根除的时间动态
  • 批准号:
    10378130
  • 财政年份:
    2019
  • 资助金额:
    $ 89.04万
  • 项目类别:
Temporal dynamics of MDRO eradication after FMT
FMT 后 MDRO 根除的时间动态
  • 批准号:
    10598519
  • 财政年份:
    2019
  • 资助金额:
    $ 89.04万
  • 项目类别:
Co-opting Endogenous Pathogen Autolysins as Next Generation Antibiotics
选择内源性病原体自溶素作为下一代抗生素
  • 批准号:
    10053699
  • 财政年份:
    2016
  • 资助金额:
    $ 89.04万
  • 项目类别:
Development of a Probiotic Therapy for Limiting Group B Streptococcal Vaginal Carriage
开发用于限制 B 族链球菌阴道携带的益生菌疗法
  • 批准号:
    9522750
  • 财政年份:
    2016
  • 资助金额:
    $ 89.04万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了